Voyager Therapeutics (VYGR) Change in Account Payables (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Change in Account Payables data on file, last reported at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 68.14% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at $89000.0 (up 101.8% YoY), and the FY2025 full-year result was $1.0 million, down 57.48% from the prior year.
• Change in Account Payables declined to -$2.3 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.0 million in Q1 2024 to a low of -$5.0 million in Q2 2024.
• A 5-year average of $126411.8 and a median of $312000.0 in 2025 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 6927.78% in 2022 and slumped 11427.78% in 2023, its largest moves.
• Tracing VYGR's Change in Account Payables over 5 years: stood at $1.2 million in 2022, then sank by 235.56% to -$1.7 million in 2023, then soared by 150.18% to $836000.0 in 2024, then surged by 246.53% to $2.9 million in 2025, then slumped by 179.05% to -$2.3 million in 2026.
• Business Quant data shows VYGR's Change in Account Payables at -$2.3 million in Q1 2026, $2.9 million in Q4 2025, and $312000.0 in Q3 2025.